Skip to content

Solid Biosciences Inc. SLDB Payments Of Stock Issuance Costs

Payments Of Stock Issuance Costs at other companies

Sana Biotechnology logo
Sana BiotechnologySANA

Other financials

Income statement

See full
Revenue$2.0M-40.6%
Operating income-$57.3M-43.1%
Net income-$56.7M-44.4%
EPS (diluted)-$0.52+11.9%

Balance sheet

See full
Cash & equivalents$297.1M+41.1%
Total debt$20.7M-12.5%
Total equity$374.1M+27.1%
Total assets$422.9M+23.0%

Cash flow

See full
Operating cash flow-$47.2M-48.3%
CapEx$165.0K+31.0%
Free cash flow-$47.4M-48.2%

Valuation

See full
Market cap$872.26M+135%
Enterprise value$595.83M+223%
P/S107.8×-9.9×

Profitability

See full
Operating margin-1,315.2%-4,060pp
Net margin-1,062.3%-251,151pp
FCF margin-1,247.7%-9,569pp

Returns & leverage

See full
Return on equity-57.4%+2.2pp
Debt / equity0.1×0.0×
Current ratio13.1×+2.2×

Where this comes from

Reported directly by Solid Biosciences Inc. in its filing.

Tagged under the XBRL concept us-gaap:PaymentsOfStockIssuanceCosts.

The official record: Solid Biosciences Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Solid Biosciences Inc.'s payments of stock issuance costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Solid Biosciences Inc.'s payments of stock issuance costs?
Solid Biosciences Inc. (SLDB) reported payments of stock issuance costs of $12.89M in Q1 2026.
What does payments of stock issuance costs mean?
This represents the aggregate cash outflows related to the issuance of equity, including registration fees, legal expenses, and other administrative costs. It provides a comprehensive view of the total cost of capital for equity-based financing. Minimizing these costs is essential for maximizing the net proceeds available for core business operations.